Bolt Biotherapeutics (BOLT) Competitors $5.88 -0.13 (-2.08%) As of 10:54 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipShort InterestTrendsBuy This Stock BOLT vs. SABS, CRIS, AMGN, GILD, VRTX, REGN, ALNY, BIIB, UTHR, and INCYShould you be buying Bolt Biotherapeutics stock or one of its competitors? The main competitors of Bolt Biotherapeutics include SAB Biotherapeutics (SABS), Curis (CRIS), Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), and Incyte (INCY). These companies are all part of the "biotechnology" industry. Bolt Biotherapeutics vs. Its Competitors SAB Biotherapeutics Curis Amgen Gilead Sciences Vertex Pharmaceuticals Regeneron Pharmaceuticals Alnylam Pharmaceuticals Biogen United Therapeutics Incyte Bolt Biotherapeutics (NASDAQ:BOLT) and SAB Biotherapeutics (NASDAQ:SABS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, risk, profitability, media sentiment, analyst recommendations, institutional ownership and valuation. Which has more volatility & risk, BOLT or SABS? Bolt Biotherapeutics has a beta of 0.91, meaning that its stock price is 9% less volatile than the S&P 500. Comparatively, SAB Biotherapeutics has a beta of 0.54, meaning that its stock price is 46% less volatile than the S&P 500. Do institutionals & insiders have more ownership in BOLT or SABS? 86.7% of Bolt Biotherapeutics shares are owned by institutional investors. Comparatively, 7.8% of SAB Biotherapeutics shares are owned by institutional investors. 6.1% of Bolt Biotherapeutics shares are owned by company insiders. Comparatively, 25.1% of SAB Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Is BOLT or SABS more profitable? Bolt Biotherapeutics' return on equity of -91.67% beat SAB Biotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Bolt BiotherapeuticsN/A -91.67% -53.19% SAB Biotherapeutics N/A -153.92%-89.16% Which has better valuation & earnings, BOLT or SABS? SAB Biotherapeutics has lower revenue, but higher earnings than Bolt Biotherapeutics. SAB Biotherapeutics is trading at a lower price-to-earnings ratio than Bolt Biotherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBolt Biotherapeutics$4.17M2.71-$63.12M-$26.66-0.22SAB Biotherapeutics$1.32M18.30-$34.10M-$4.00-0.58 Do analysts recommend BOLT or SABS? Bolt Biotherapeutics currently has a consensus target price of $47.50, indicating a potential upside of 707.14%. SAB Biotherapeutics has a consensus target price of $9.33, indicating a potential upside of 302.30%. Given Bolt Biotherapeutics' higher probable upside, analysts plainly believe Bolt Biotherapeutics is more favorable than SAB Biotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bolt Biotherapeutics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00SAB Biotherapeutics 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80 Does the media prefer BOLT or SABS? In the previous week, SAB Biotherapeutics had 3 more articles in the media than Bolt Biotherapeutics. MarketBeat recorded 5 mentions for SAB Biotherapeutics and 2 mentions for Bolt Biotherapeutics. Bolt Biotherapeutics' average media sentiment score of 0.95 beat SAB Biotherapeutics' score of 0.48 indicating that Bolt Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bolt Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SAB Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryBolt Biotherapeutics and SAB Biotherapeutics tied by winning 8 of the 16 factors compared between the two stocks. Get Bolt Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BOLT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BOLT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BOLT vs. The Competition Export to ExcelMetricBolt BiotherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.29M$3.42B$6.16B$10.59BDividend YieldN/A2.30%5.73%4.78%P/E Ratio-0.2223.1085.6727.43Price / Sales2.71450.35584.77183.24Price / CashN/A46.1137.3961.86Price / Book0.2010.6812.516.79Net Income-$63.12M-$52.47M$3.32B$276.90M7 Day Performance-0.17%1.08%707.60%0.29%1 Month Performance14.49%16.86%935.16%7.59%1 Year Performance-54.02%16.25%2,403.40%39.41% Bolt Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BOLTBolt Biotherapeutics2.7316 of 5 stars$5.89-2.1%$47.50+707.1%-52.3%$11.29M$4.17M-0.2290News CoverageSABSSAB Biotherapeutics3.9312 of 5 stars$2.29+11.2%$9.75+325.8%-2.9%$21.45M$1.32M-0.57140News CoverageAnalyst ForecastGap UpHigh Trading VolumeCRISCuris2.2754 of 5 stars$1.66+0.6%$17.00+924.1%-71.6%$20.62M$10.91M-0.3460AMGNAmgen4.5317 of 5 stars$294.12-1.3%$309.42+5.2%-8.5%$160.37B$33.42B24.0528,000Positive NewsAnalyst RevisionGILDGilead Sciences4.8819 of 5 stars$113.58+0.8%$117.17+3.2%+37.8%$139.83B$28.86B22.6317,600Positive NewsVRTXVertex Pharmaceuticals4.7994 of 5 stars$402.90-0.1%$493.81+22.6%-15.8%$103.40B$11.02B28.806,100Positive NewsAnalyst RevisionREGNRegeneron Pharmaceuticals4.7585 of 5 stars$585.48-2.4%$817.67+39.7%-43.3%$63.59B$14.20B14.7615,106Analyst ForecastAnalyst RevisionALNYAlnylam Pharmaceuticals4.014 of 5 stars$452.00-1.0%$448.04-0.9%+63.7%$59.82B$2.46B-183.002,230Trending NewsAnalyst ForecastAnalyst RevisionBIIBBiogen4.634 of 5 stars$154.05-3.6%$180.04+16.9%-25.0%$23.44B$9.68B14.737,605Trending NewsAnalyst ForecastAnalyst RevisionUTHRUnited Therapeutics4.3041 of 5 stars$453.28+0.0%$449.57-0.8%+20.2%$20.44B$2.88B17.691,305Insider TradeINCYIncyte4.4028 of 5 stars$87.23+0.4%$83.64-4.1%+33.0%$17.03B$4.58B19.832,617 Related Companies and Tools Related Companies SAB Biotherapeutics Alternatives Curis Alternatives Amgen Alternatives Gilead Sciences Alternatives Vertex Pharmaceuticals Alternatives Regeneron Pharmaceuticals Alternatives Alnylam Pharmaceuticals Alternatives Biogen Alternatives United Therapeutics Alternatives Incyte Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BOLT) was last updated on 10/16/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredOptions Pro Reveals His #1 Retirement Income TradeIf you can be at your computer between 9 a.m. and 10:45 a.m. on most weekdays, I’ll show you a simple trading ...Base Camp Trading | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredNvidia’s slow death marchEric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | SponsoredWhat the hell is going on, America?America’s $37.5 trillion debt spiral, soaring deficits, and repeated credit downgrades are exactly what Porter...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bolt Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bolt Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
